top of page

Free Biopharma Daily Stock Updates - 01/25/22

Updated: Jan 28, 2022

$XBI $91.38 | -0.80%

 

Covid Updates

$VALN +6.5% Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate source


$PFE +1.9% & $BNTX +3.7% Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age. source



Pipeline Updates

$SRRA +46.2% Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis source


$INCY -1.6% Incyte Provides Update on Parsaclisib and MCLA-145 source


$ANVS +1.5% Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease. source


$ORIC -3.1% ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications. source


$BMEA +1.1% Biomea Fusion Announces First Patient Dosed. source


$ARCT +1.7% Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial. source


$CBIO -7.1% Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency. source


$CKPT +12.3% Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma. source


$ATHA -1.5% Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies. source


$IMRA -4.5% Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF). source


$PTCT -2.4% FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy. source



Business Updates

$CAPR +21.6% Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S. source


$SRRA +46.2% Sierra Oncology Announces Proposed Public Offering of Common Stock source


$OTLK +0.7% Outlook Therapeutics Provides a Corporate Update and Business Outlook. source


$SRRA +46.2% Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib. source


$MTNB -16.2% Matinas BioPharma Provides Business Update and 2022 Strategic Outlook. source


 

Posted by FS/JM

0 comments
bottom of page